Stocks and Investing
Stocks and Investing
Thu, June 29, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gil Blum Reiterated (TSHA) at Strong Buy and Held Target at $6 on, Jun 29th, 2023
Gil Blum of Needham, Reiterated "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy and Held Target at $6 on, Jun 29th, 2023.
Gil has made no other calls on TSHA in the last 4 months.
There are 5 other peers that have a rating on TSHA. Out of the 5 peers that are also analyzing TSHA, 1 agrees with Gil's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michael Lapides of "Morgan Stanley" Maintained at Hold with Decreased Target to $1 on, Thursday, March 30th, 2023
These are the ratings of the 4 analyists that currently disagree with Gil
- Joon Lee of "Truist Securities" Maintained at Strong Buy with Decreased Target to $2 on, Monday, May 15th, 2023
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $2 on, Thursday, March 30th, 2023
- Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $4 on, Thursday, March 30th, 2023
- Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $5 on, Thursday, March 30th, 2023
Contributing Sources